

Unaudited Financial Results for the Quarter ended 30th June, 2011

(Rs. in Lacs)

Particulars	For Quarter ended		For Year Ended
	30.06.11	30.06.10	31.03.11
	(Unaudited)	(Unaudited)	(Audited)
1. (a) Net Turnover / Income from Operations	22,099	25,390	113,046
(b) Other Operating Income	470	451	2,193
Total Income	22,569	25,841	115,239
2. Expenditure			
a. (Increase)/decrease in stock in trade and work in progress	(6,549)	3,290	5,887
b. Consumption of materials	14,586	8,309	44,576
c. Purchase of traded goods	607	537	2,444
d. Manufacturing & Administrative expenditure	2,649	2,375	10,793
e. Research & Development expenditure	1,327	1,268	5,946
f. Employees cost	3,049	2,851	12,939
g. Depreciation	1,632	1,737	7,311
h. Other expenditure	1,596	1,066	5,935
i. Total	18,897	21,433	95,831
3. Profit from Operations before other income, Interest, Foreign Exchange Fluctuation Gain/ (Loss) & Exceptional items (1-2)	3,672	4,408	19,408
4. Other Income	167	126	1,312
5. Profit before Interest, Foreign Exchange Fluctuation Gain/ (Loss) & Exceptional items (3+4)	3,839	4,534	20,720
6. Interest	1,631	856	4,780
7. Exchange Fluctuation Loss/ (Gain)	136	139	391
8. Profit after Interest but before Exceptional items (5-6+7)	2,072	3,539	15,549
9. Exceptional items	-	-	-
10. Profit / (Loss) from Ordinary Activities before tax (8+9)	2,072	3,539	15,549
11. Tax expenses	400	284	2,044
12. Net Profit / (Loss) from Ordinary Activities after tax (10-11)	1,672	3,255	13,505
13. Extraordinary items (net of tax expenses)	-	-	-
14. Net Profit / (Loss) for the period (12-13)	1,672	3,255	13,505
15. Paid up equity share capital (face value of Re. 1 per share)	613	668	613
16. Reserves excluding Revaluation Reserves	2,73	4,87	21,35
17. Earning Per Share (EPS) - Basic	2.73	4.56	21.35
- Diluted	-	-	-
18. Public shareholding			
- No. of shares	15,369,872	20,904,912	15,364,465
- Percentage of shareholding	25.09	31.27	25.08
19. Promoters and promoter group Shareholding			
a) Pledge / Encumbered	38,000	38,000	38,000
- Number of Shares	0.08	0.08	0.08
- % of Shares (as a % of the total shareholding of promoter & promoter group)	0.06	0.06	0.06
b) Non-encumbered	45,842,874	45,899,834	45,848,281
- Number of Shares	99.92	99.92	99.92
- % of Shares (as a % of the total shareholding of promoter & promoter group)	74.85	68.67	74.86

Wild

Unaudited Segment-wise Revenue, Results, and Capital Employed

1. Segment Revenue					
(a) Vaccines	13,643		17,676		83,787
(b) Formulations	8,618		7,868		30,073
(c) Research & Development	-		-		-
(d) Unallocated	308		297		1,379
Gross Sale/Income from Operation	22,569		25,841		115,239
Less : Inter Segment Revenue	-		-		-
Net Sales/Income from Operations	22,569		25,841		115,239
2. Segment Results Profit (+) before tax and interest from each segment					
(a) Vaccines	4,924		4,910		29,512
(b) Formulations	2,391		2,506		5,711
(c) Research & Development	(1,710)		(1,657)		(7,531)
(d) Unallocated	-		-		-
Total	5,605		5,759		27,692
Less : i) Interest	1,631		856		4,780
ii) Other Un-allocated Expenditure net off Un-allocated income.	1,902		1,364		7,363
Total Profit Before Tax	2,072		3,539		15,549
3. Capital Employed					
(Segment Assets-Segment Liabilities)					
(a) Vaccines	75,089		73,743		79,443
(b) Formulations	18,991		19,494		17,641
(c) Research & Development	20,990		21,621		21,248
(d) Unallocated	(49,719)		(41,968)		(54,654)
Total Capital Employed	65,351		72,890		63,678

New Delhi

Regd. Office : Ambala-Chandigarh Highway, Lajru- 140501, Punjab

Website : <http://www.paracee-biotec.com>

Handwritten signature/initials

Notes:

1	The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their meetings held on July 26, 2011 and July 27, 2011, respectively.
2	Tax expense includes provision for income tax and deferred tax.
3	The Company's Share Transfer Books and Register of Members will remain closed from September 21, 2011 to September 24, 2011 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on September 24, 2011, in compliance of clause 16 of the Listing Agreement.
4	During the quarter, the Company has invested an amount of Rs. 800 lacs for acquiring 266,666 Optionally Convertible Preference Shares in its wholly-owned subsidiary (WOS) company, Best On Health Limited
5	The Company has invested an amount of Rs. 70.5 Lac towards payment of call money during the quarter ended June 30, 2011 in respect of partly paid shares held in its Indian subsidiary, NewRise Healthcare Pvt. Ltd.
6	During the quarter, Company's WOS Panacea Biotech Inc., incorporated in USA has been dissolved on April 5, 2011 and the available amount of USD 24,087.52 (out of total investment of US\$50,100) has been remitted back in India subsequent to the Quarter ended June 30, 2011.
7	During the quarter under review, the Company provided a loan of US\$ 350,000 (Rs. 155.68 Lacs) to its overseas WOS Rees Investments Limited.
8	During the quarter, the Company has launched 8 new products namely TecPara (for Antipruritic), Nimulid ER (Pain Killer), Fotizo Powder (Protein for Cancer Patients), Tecbeta 25 & 50 and Tecbeta AM (For Hypertension), Gilben Total P (Anti Diabetic), Stamnicar Total P (Giving energy to Heart muscle), Ferbato 40 & 80 (for Hypertension).
9	As regards Auditors' observations in their report on the Audited Accounts for the Financial Year 2010-11:
i)	With regard to capitalization of expenditure on clinical trials for the purpose of registration of Company's products outside India primarily in US or Europe, the management believes that these products would be commercially viable and there is no reason to believe that there is any uncertainty that may lead to not securing registration for the products from the regulatory authorities. An amount of Rs. 249 Lacs towards the above said expenditure on clinical trials during the quarter ended June 30, 2011, has also been capitalized on similar grounds. The total amount of such capitalization up to June 30, 2011 is Rs. 6,213 Lacs.
ii)	With regard to payment of managerial remuneration of Rs. 382 Lacs during Financial Year 2008-09, in excess of limits prescribed under Section 198 and 309 read with Part II of Schedule XIII of the Companies, Act, 1956, without obtaining Central Government approval, the Company sought approval of the Central Government for such remuneration. Approvals to the extent of Rs. 291 Lacs of excess remuneration were received in earlier years and the requisite approvals for waiver of balance amount of excess remuneration of Rs. 91 Lacs had also been received during the quarter ended June 30, 2011.
10	The Statutory Auditors have also carried out limited review of these results and have given their observations in their report in respect of para 9(i) above.
11	Status of Investors' complaints [in nos.] during the quarter, pursuant to clause 41 of listing agreement: Opening [2]; Received [0]; Disposed [2]; Closing [0].
12	The necessary Certificate in respect of above Results in terms of requirement of clause 41 of the Listing Agreement, has been placed before the Board of Directors.
13	The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary.
14	The above results are also available on the Company's website viz. http://www.panacea-biotech.com .

For and on behalf of the Board

New Delhi
July 27, 2011

Dr. Rajesh Jain
Joint Managing Director

Panacea Biotech Limited

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab

<http://www.panacea-biotech.com>

